A compound of formula (Ia) or a stereoisomer, pharmaceutically acceptable salt, oxide or solvate thereof, wherein A is C 6-8 cycloalkenyl optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, C 1-6 alkyl, and C 2-6 alkenyl; R 1 is halogen, OH, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, wherein C 2-6 alkenyl is optionally substituted from 1 to 3 times with aryl, and wherein aryl is optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, OH, and C 1-6 alkyl; R 2 is hydrogen or C 6-8 cycloalkenyl, wherein C 6-8 cycloalkenyl is optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, C 1-6 alkyl, and C 2-6 alkenyl; R 3 is halogen, OH, C 2-6 alkenyl, or C 2-6 alkynyl, wherein C 2-6 alkenyl is optionally substituted from 1 to 3 times with aryl, and wherein aryl is optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, OH, and C 1-6 alkyl; R 4 is hydrogen or C 6-8 cycloalkenyl, wherein C 6-8 cycloalkenyl is optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, C 1-6 alkyl, and C 2-6 alkenyl; and R 5 is halogen, OH, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, wherein C 2-6 alkenyl is optionally substituted from 1 to 3 times with aryl, and wherein aryl is optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, OH, and C 1-6 alkyl, for use in a method for the treatment of a disease or disorder associated with Trpv2 activity, which disease or disorder associated with Trpv2 activity is selected from the group consisting of psoriasis, psoriatic arthritis, inflammatory diseases, asthma and cancer. A is C 6-8 cycloalkenyl optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, C 1-6 alkyl, and C 2-6 alkenyl; R 1 is halogen, OH, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, wherein C 2-6 alkenyl is optionally substituted from 1 to 3 times with aryl, and wherein aryl is optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, OH, and C 1-6 alkyl; R 2 is hydrogen or C 6-8 cycloalkenyl, wherein C 6-8 cycloalkenyl is optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, C 1-6 alkyl, and C 2-6 alkenyl; R 3 is halogen, OH, C 2-6 alkenyl, or C 2-6 alkynyl, wherein C 2-6 alkenyl is optionally substituted from 1 to 3 times with aryl, and wherein aryl is optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, OH, and C 1-6 alkyl; R 4 is hydrogen or C 6-8 cycloalkenyl, wherein C 6-8 cycloalkenyl is optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, C 1-6 alkyl, and C 2-6 alkenyl; and R 5 is halogen, OH, C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, wherein C 2-6 alkenyl is optionally substituted from 1 to 3 times with aryl, and wherein aryl is optionally substituted from 1 to 3 times with substituents independently selected from the group consisting of hydrogen, OH, and C 1-6 alkyl, for use in a method for the treatment of a disease or disorder associated with Trpv2 activity, which disease or disorder associated with Trpv2 activity is selected from the group consisting of psoriasis, psoriatic arthritis, inflammatory diseases, asthma and cancer.